4-Hydroxytamoxifen – (82413-23-8)

Afimoxifene, also known as 4-hydroxytamoxifen is a selective estrogen receptor modulator (SERM) of the triphenylethylene group and an active metabolite of tamoxifen. It is under development as a topical gel for the treatment of breast hyperplasia and has completed a phase II clinical trial for cyclical mastalgia.

Afimoxifene acts as a tissue-selective agonist-antagonist of estrogen receptors ERα and ERβ, with mixed estrogenic and antiestrogenic activity depending on the tissue. It also acts as an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity and as an antagonist of estrogen-related receptors (ERRs) ERRβ and ERRγ.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Afimoxifene
https://www.medchemexpress.com/4-Hydroxytamoxifen.html
https://www.selleckchem.com/products/4-hydroxytamoxifen-4-ht-afimoxifene.html